Helicobacter Pylori Infections - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 59

Helicobacter Pylori Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H2 2012', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections. 'Helicobacter Pylori Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Helicobacter Pylori Infections.
- A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Helicobacter Pylori Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Helicobacter Pylori Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Helicobacter Pylori Infections Therapeutic Products under Development, Key Players in Helicobacter Pylori Infections Therapeutics, Helicobacter Pylori Infections Pipeline Overview, Helicobacter Pylori Infections Pipeline, Helicobacter Pylori Infections Pipeline Assessment

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Helicobacter Pylori Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Helicobacter Pylori Infections 8
Helicobacter Pylori Infections Therapeutics under Development by Companies 10
Helicobacter Pylori Infections Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Helicobacter Pylori Infections Therapeutics – Products under Development by Companies 17
Helicobacter Pylori Infections Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Helicobacter Pylori Infections Therapeutics Development 19
Sequella, Inc. 19
Affinium Pharmaceuticals, Inc. 20
Deva Holding A.S. 21
MerLion Pharmaceuticals Pte Ltd 22
EpiVax, Inc. 23
Vecta Ltd. 24
HeliCure AB 25
Helicobacter Pylori Infections – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
SQ 109 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVEC - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Rifalazil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
H.Pylori Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Amoxicillin + Bismuth + Clarithromycin + Metronidazole + Omeprazole + Tetracycline - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
Lansoprazole + Amoxicillin + Clarithromycin + Metronidazole - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GT08 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Finafloxacin Oral - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Sitafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RHB 105 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Fabl Inhibitor Program - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Helicobacter Pylori Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Helicobacter Pylori Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Helicobacter Pylori Infections Therapeutics – Drug Profile Updates 50
Helicobacter Pylori Infections Therapeutics - Dormant Products 52
Helicobacter Pylori Infections – Product Development Milestones 53
Featured News & Press Releases 53
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 53
Oct 29, 2010: AstraZeneca announces co-promotion agreement with Daiichi Sankyo for NEXIUM in Japan 53
Sep 27, 2010: TrioBiotics Pharma AG Announces Receipt Of Notice Of Allowance Of Patent For Rifalazil For Method Of Treatment And Prophylactic Use 54
Aug 09, 2010: TrioBiotics Pharma AG Announces New Strategic Direction To Focus On Rifalazil Development 54
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 55
May 01, 2008: FDA approves Nexium for the treatment of short-term GERD in children 1 to 11 years old 55
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation With Ranbaxy 56
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 56
Oct 09, 2007: EPO Rules European Nexium Process Patent Valid 57
Dec 19, 2006: EPO Announces European Nexium Substance Patent Decision 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Helicobacter Pylori Infections, H2 2012 8
Products under Development for Helicobacter Pylori Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Sequella, Inc., H2 2012 19
Affinium Pharmaceuticals, Inc., H2 2012 20
Deva Holding A.S., H2 2012 21
MerLion Pharmaceuticals Pte Ltd, H2 2012 22
EpiVax, Inc., H2 2012 23
Vecta Ltd., H2 2012 24
HeliCure AB, H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Helicobacter Pylori Infections Therapeutics – Drug Profile Updates 50
Helicobacter Pylori Infections Therapeutics – Dormant Products 52

List of Figures
Number of Products under Development for Helicobacter Pylori Infections, H2 2012 8
Products under Development for Helicobacter Pylori Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Customers who bought this item also bought

• Gastric Ulcers - Pipeline Review, H2 2012
• Peptic Ulcers - Pipeline Review, H2 2012
• Ulcers - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Urinary Tract Infections - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Other Bacterial Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Bacterial Respiratory Tract Infections - Pipeline Review, H2 2012